Laxxon Medical Announces Development Program for Non-Invasive, 3D Printed
Oral GLP-1 Asset, Offering an Alternative to GLP-1 Injections on Market

   Laxxon Medical Announces Development Program for Non-Invasive, 3D
   Printed Oral GLP-1 Asset, Offering an Alternative to GLP-1
   Injections on Market
   New York, 05/22/2024 / 09:05, EST/EDT - EQS Newswire - Laxxon
   Medical

Laxxon Medical announced today the development program for LXM.2, a 3D
printed oral glucagon-like peptide-1 (GLP-1) receptor agonist for the
treatment of adults and pediatric patients 12 years and older with obesity.

LXM.2 is an enterically coated oral solid tablet consisting of a GLP-1
receptor agonist combined with a permeation enhancer intended to increase
bioavailability. The addition of the permeation enhancer was made possible
using Laxxon Medical's SPID� (Screen Printed Innovative Drug) platform
technology.

"Polypeptides and proteins like GLP-1s are known to have low bioavailability
due to the degradation in the GI tract and poor uptake, meaning they need
protection from degradation and their absorption benefits from permeation
enhancers. Traditionally, it has been difficult to manufacture products
containing the permeation enhancer via conventional methods, such as direct
compression or granulation, given its physicochemical properties. It has
additionally been challenging for these traditional manufacturing methods to
apply an enteric coating to the finished product." said Dr. Achim
Schneeberger, Laxxon Medical's Chief Scientific Officer. "SPID�-Technology
is not only characterized by precise and tailored dosing - its unique
formulation allows manufacturing of oral solids containing clinically
relevant doses of permeation enhancers at convincing hardness and low
friability."

The active pharmaceutical ingredient (API) in LXM.2 has already been
approved by the FDA for use in adults and pediatric patients 12 years and
older with obesity. LXM.2 is eligible to be developed using the 505(b)2
pathway. Laxxon has designed a streamlined development program and is
targeting an NDA submission in early 2027.

Laxxon Medical CEO Helmut Kerschbaumer said: "LXM.2 would be a game-changer
for patients struggling with obesity. Injectable medications, while
effective, can be inconvenient and pose a barrier for some people. An oral
option would offer greater ease of use and potentially improve adherence to
treatment. This could significantly increase the number of patients who can
successfully manage their weight and achieve long-term health benefits. The
ability to use the 505(b)2 pathway means we can potentially get LXM.2 to
patients quickly."

Laxxon is seeking to partner or out-license LXM.2. A team of Laxxon Medical
representatives will be attending BIO in San Diego, June 3-8, 2024.

Read more about LXM.2 here.

About Laxxon Medical

Laxxon Medical is a pharma-technology company pioneering a new generation of
advanced pharmaceuticals with SPID�, a novel 3D screen printing platform
technology. For new and common pharmaceutical drugs, SPID� unlocks
innovative drug delivery advancements paired with fast-tracked market access
and extensive IP protection to yield disruptive opportunities for partners
and life-changing results for patients.

Laxxon's pipeline includes ongoing working-projects with notable pharma
players, biotech companies and research universities, in addition to 13
in-house Advanced Patented Generics products. Laxxon's IP is continuously
growing and consists of 150 patents and patent applications with more than
3,000 patent claims.

Investor Contact: Alexander Ruckdaeschel, Chief Strategy Director
alexander.ruckdaeschel@laxxonmedical.com

Business Development Contact: Jessica McHargue, Director of Business
Development jessica.mchargue@laxxonmedical.com

Media Contact: Frances Hoggard, Communications Manager
frances.hoggard@laxxonmedical.com

SOURCE: Laxxon Medical


05/22/2024 EQS Newswire / EQS Group AG